EDINBURGH, Scotland, Feb. 19, 2026 /PRNewswire/ -- Lario Therapeutics ("Lario" or the "Company"), a biopharmaceutical company developing first-in-class precision medicines for epileptic and ...
Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD Lario Therapeutics has secured $2.4 million in new grant funding from The Michael J Fox Foundation for Parkinson’s Research ...
Some key stats from Diamondback Energy’s two Midland Basin bolt-on deals: 83,000 net acres; 448 new net drilling locations; and about two years. Roughly 24 months is the incremental inventory life ...
The neurological disease is estimated to affect more than ten million people globally The Michael J. Fox Foundation (MJFF) has awarded $6m to Lario Therapeutics to fund its preclinical programme for ...
Despite opposition from foothill communities, the U.S. Environmental Protection Agency is moving forward with its plan to use an Irwindale site to process hazardous debris from the Eaton Fire. For the ...
EDINBURGH, Scotland--(BUSINESS WIRE)--Lario Therapeutics (‘Lario’, or ‘the Company’), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders ...
Lario Therapeutics (‘Lario Tx’, or ‘the Company’), a biopharmaceutical company developing first-in-class precision medicines that are targeting disease-modifying treatments for severe neurological ...
New prestigious grants support Lario’s unique portfolio of calcium channel programmes Indication expansion into Parkinson’s disease, and PTSD (post-traumatic stress disorders) Builds on prior support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results